Since TKIs represent a first line targeting approach for CML, next, we tested if targeting miR-142 deficit and/or the consequential PD-1 upregulation enhanced TKI activity in BC models. Here, PDCD1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.